Literature DB >> 10590328

Hepatitis A and hepatitis B vaccinations: immunogenicity of combined vaccine and of simultaneously or separately applied single vaccines.

P A Czeschinski1, N Binding, U Witting.   

Abstract

The vaccination success and side effects of hepatitis A and hepatitis B immunisation of health care employees when using a combined vaccine were compared to those observed with simultaneous or single immunisations. The immunological response of two groups of healthy participants (75 each) receiving either single HAV or HBV vaccination was compared with that of two groups (75 each) vaccinated either simultaneously with both vaccines or with the combined vaccine. There were no non or low responders with respect to hepatitis A vaccination. Only one participant failed to build up an anti-HBs titer after combined vaccination. The good tolerance of separate, simultaneous and combined vaccinations was confirmed. Both combined and simultaneous vaccination led to significantly higher anti-HAV titers than single immunisation, while markedly but not significantly higher anti-HBs titers were found only with simultaneous vaccination. Considering the additional advantage of the higher acceptance of only one injection with the combined vaccine, this vaccination should be recommended for employees at risk for both hepatitis A and hepatitis B.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10590328     DOI: 10.1016/s0264-410x(99)00354-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.

Authors:  Li Qin; Peter B Gilbert; Dean Follmann; Dongfeng Li
Journal:  Ann Appl Stat       Date:  2008-03       Impact factor: 2.083

2.  Hepatitis C services and individuals with serious mental illness.

Authors:  Richard W Goldberg; Puja Seth
Journal:  Community Ment Health J       Date:  2008-05-09

3.  Determinants of hepatitis A vaccine immunity in a cohort of human immunodeficiency virus-infected children living in Switzerland.

Authors:  Pierre Alex Crisinel; Klara Maria Posfay-Barbe; Christoph Aebi; Jean-Jacques Cheseaux; Christian Kahlert; Christoph Rudin; David Nadal; Claire-Anne Siegrist
Journal:  Clin Vaccine Immunol       Date:  2012-08-29

4.  A combined inactivated cholera and hepatitis A vaccine-induced potent protective immunity in a mouse model.

Authors:  Nourhan H AbdelAllah; Ahmed F Azmy; Mohamed E Rashed; Sameh AbdelGhani; Yasser Gaber
Journal:  Appl Microbiol Biotechnol       Date:  2022-10-21       Impact factor: 5.560

5.  Assessing vaccine effects in repeated low-dose challenge experiments.

Authors:  Michael G Hudgens; Peter B Gilbert
Journal:  Biometrics       Date:  2009-12       Impact factor: 2.571

Review 6.  Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability.

Authors:  David L Murdoch; Karen Goa; David P Figgitt
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens.

Authors:  Peter B Gilbert; Douglas Grove; Erin Gabriel; Ying Huang; Glenda Gray; Scott M Hammer; Susan P Buchbinder; James Kublin; Lawrence Corey; Steven G Self
Journal:  Stat Commun Infect Dis       Date:  2011-10

9.  Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.

Authors:  Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris
Journal:  MMWR Recomm Rep       Date:  2020-07-03

Review 10.  Hepatitis A, hepatitis B, and combination hepatitis vaccines for immunoprophylaxis: an update.

Authors:  Raymond S Koff
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.